Trustmark National Bank Trust Department Has Upped Its Glaxosmithkline Plc (GSK) Position; Rock Springs Capital Management LP Has Increased Insmed (INSM) Position

February 20, 2018 - By Darrin Black

Trustmark National Bank Trust Department increased Glaxosmithkline Plc (GSK) stake by 181.56% reported in 2017Q3 SEC filing. Trustmark National Bank Trust Department acquired 26,019 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Trustmark National Bank Trust Department holds 40,350 shares with $1.64 million value, up from 14,331 last quarter. Glaxosmithkline Plc now has $84.07 billion valuation. The stock decreased 0.21% or $0.08 during the last trading session, reaching $37.62. About 1.88M shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since February 20, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

Rock Springs Capital Management Lp increased Insmed Inc (INSM) stake by 38.89% reported in 2017Q3 SEC filing. Rock Springs Capital Management Lp acquired 182,000 shares as Insmed Inc (INSM)’s stock rose 11.02%. The Rock Springs Capital Management Lp holds 650,000 shares with $20.29M value, up from 468,000 last quarter. Insmed Inc now has $1.85 billion valuation. The stock decreased 0.21% or $0.05 during the last trading session, reaching $24.18. About 94,440 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 57.88% since February 20, 2017 and is uptrending. It has outperformed by 41.18% the S&P500.

Among 10 analysts covering Insmed (NASDAQ:INSM), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Insmed had 25 analyst reports since August 10, 2015 according to SRatingsIntel. Robert W. Baird initiated the shares of INSM in report on Monday, July 10 with “Buy” rating. The company was maintained on Wednesday, September 6 by H.C. Wainwright. The company was upgraded on Thursday, August 20 by Zacks. As per Thursday, November 2, the company rating was maintained by Stifel Nicolaus. As per Thursday, January 4, the company rating was maintained by Robert W. Baird. On Monday, September 11 the stock rating was maintained by Cowen & Co with “Buy”. Robert W. Baird maintained the stock with “Buy” rating in Wednesday, September 6 report. Evercore initiated the stock with “Buy” rating in Wednesday, August 16 report. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Buy” rating by Stifel Nicolaus on Thursday, January 4. Stifel Nicolaus initiated the shares of INSM in report on Tuesday, March 15 with “Buy” rating.

Investors sentiment increased to 3.74 in Q3 2017. Its up 1.98, from 1.76 in 2017Q2. It is positive, as 11 investors sold INSM shares while 16 reduced holdings. 44 funds opened positions while 57 raised stakes. 144.25 million shares or 160.06% more from 55.47 million shares in 2017Q2 were reported. Moreover, Meeder Asset Mgmt has 0% invested in Insmed Incorporated (NASDAQ:INSM). Great West Life Assurance Can holds 0% or 6,882 shares. Iguana Healthcare Management Limited Liability holds 50,000 shares or 0.87% of its portfolio. Vanguard Grp accumulated 0.01% or 4.67M shares. New York State Common Retirement Fund holds 67,100 shares or 0% of its portfolio. Thompson Davis And invested in 500 shares or 0.03% of the stock. 948,115 are owned by Northern Trust. Td Asset has 0.01% invested in Insmed Incorporated (NASDAQ:INSM). Moreover, Baker Bros Advsrs Ltd Partnership has 0.18% invested in Insmed Incorporated (NASDAQ:INSM) for 700,000 shares. Moreover, Fmr Ltd Liability Co has 0.04% invested in Insmed Incorporated (NASDAQ:INSM). Sg Americas Ltd Liability reported 14,289 shares or 0% of all its holdings. Bnp Paribas Arbitrage holds 0% or 8,365 shares in its portfolio. Sectoral Asset Mngmt Inc has 62,399 shares for 0.25% of their portfolio. Franklin Street Advsr Nc reported 15,800 shares or 0.08% of all its holdings. Eam Investors Limited Liability Corporation reported 0.36% stake.

Rock Springs Capital Management Lp decreased Mersana Therapeutics Inc stake by 197,893 shares to 1.33M valued at $23.00 million in 2017Q3. It also reduced G1 Therapeutics Inc stake by 72,188 shares and now owns 240,000 shares. Coherus Biosciences Inc (NASDAQ:CHRS) was reduced too.

Since September 5, 2017, it had 0 insider purchases, and 2 sales for $2.70 million activity. SHAROKY MELVIN MD sold $1.37 million worth of Insmed Incorporated (NASDAQ:INSM) on Tuesday, September 5. 45,000 shares were sold by HAYDEN DONALD J JR, worth $1.34M.

Trustmark National Bank Trust Department decreased Prospect Capital Corporation (NASDAQ:PSEC) stake by 141,451 shares to 215,890 valued at $1.45M in 2017Q3. It also reduced Crown Castle International (NYSE:CCI) stake by 5,018 shares and now owns 4,867 shares. Vanguard (VCSH) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: